# **Incremental Progress Report**

#### **Incremental Progress Report – EUPHEM cohort 4**

From: Name

**Cohort:** Cohort number **Training site supervisor:** Name of supervisor

**Update from:** Current Date

Note: please indicate changes from last IPR in red

1) Administrative Matters:

Date:	Topic:	Status:	Please describe procedure, difficulties, timelines and reason for not completing
Put date	List and comment on administrative issues relevant to the training programme (salaries, insurance, hosting office, communication means, reimbursements etc.).	Put status (starting, ongoing, completed)	

2) Outbreak Investigations:

Date:	Type of outbreak and your involvement:	Status:	Please describe procedure, difficulties, timelines and reason for not completing
Put date	Describe any involvement in outbreak investigations.  Each completed outbreak investigation should be detailed in a summary <15 lines (context, investigation team, objectives, methods, results, conclusion, recommendations and actions).  Please state also your role and if you were main investigator.  Main investigator: Yes/No	Put status (starting, ongoing, completed)	

3) Surveillance Activities:

Date:	Type of surveillance and your involvement:	Status:	Please describe procedure, difficulties, timelines and reason for not completing
Put date	Summarise activities related to epidemiological surveillance, including protocols, data analysis and reports developed to set up surveillance systems, evaluation schemes and results of surveillance data analyses. Please state also your role.	Put status (starting, ongoing, completed)	

4) Research Activities:

Date:	Type of research and your involvement:	Status:	Please describe procedure, difficulties, timelines and reason for not completing
Put date	Summarise research protocols, study reports or manuscripts written during the last three months. The summary should include: objectives, methods, results, recommendations and public health impact. Please state also your role.	Put status (starting, ongoing, completed)	,

5) Biosafety/biosecurity activities

-,	The second section of the section of th		
Date:	Type of activity and your involvement:	Remarks:	Please describe procedure, difficulties, timelines and reason for not completing
Put date	List the context and content of various activities which you helped to plan, develop or undertook. State the objectives, content, audience and location of the activity.	Put status (starting, ongoing, completed)	

# 6) Quality management

Date:	Type of activity and your involvement:	Remarks:	Please describe procedure, difficulties, timelines and reason for not completing
Put date	List the context and content of various activities which you helped to plan, develop or undertook. State the objectives, content, audience and location of the activity.	Put status (starting, ongoing, completed)	

7) Training activities:

Date:	Type of training followed:	Status:	Please describe procedure, difficulties, timelines and reason for not completing	
Put date	<ul> <li>a) List all training sessions which you attended during the reporting period, and include comments on their content. This information should also help to publicise training site or host country training opportunities.</li> </ul>	Put status (starting, ongoing, completed)		
	b) List the optional EPIET modules you have attended. Compulsory modules do not need to be mentioned.			

c) Include the visits to the laboratories.  Specify the length and the type of activities you were involved with.		

8) Teaching Activities:

I lyno of toaching and your involvements		
Type of teaching and your involvement:	Remarks:	Please describe procedure, difficulties, timelines and reason for not completing
List the context and content of various teaching sessions which you helped to plan, develop or undertook. State the objectives, content, audience and location of the courses.	Put status (starting, ongoing, completed)	
	sessions which you helped to plan, develop or undertook. State the objectives, content, audience	sessions which you helped to plan, develop or ongoing, undertook. State the objectives, content, audience completed)

9) Management and Communication:

Date:	Type of communication (including publications and presentations):	Remarks:	Please describe procedure, difficulties, timelines and reason for not completing
Put date	<ul> <li>a) List all on call/ telephone help-line duties, TV and radio interviews, question and answers briefs, preparation of press releases, public health decision and policymaking sessions, oral scientific presentation, and poster presentations. List all scientific reports and manuscripts in preparation.</li> </ul>	Put status (starting, ongoing, completed)	
	<ul> <li>b) List all publications, referenced using         Vancouver style and organised according to type of article and type of journal:         <ul> <li>Epidemiological bulletin</li> <li>National or regional journals (state whether peer-reviewed)</li> <li>International journals</li> </ul> </li> </ul>		

**10) Other:** 

Date:	Type of activity and your involvement:	Remarks:	Please describe procedure, difficulties, timelines and reason for not completing
Put date	Short description of any other activity and your involvement	Put status (starting, ongoing, completed)	

# **Annex 3 Example of progress report (please notice difference in current version format)**

# Incremental Progress Report – EUPHEM Cohort 1

From: Satu Kurkela, EUPHEM Fellow C1

Cohort: 1

**Update from:** 18.8.2010

#### 1) Administrative Matters:

Date:	Topic:	Status:
2.11.2008	Found a flat and moved in. Opened local bank account.	Completed
05.11.2008	Submitted the following documents to ECDC: Financial Identification, Daily allowance request, Travel imbursement request	Completed
25.3.2009	Installation allowance received.	Completed
11.8.2010	David Brown has sent an outline of the specific activities of my EUPHEM fellowship to the responsible body of the medical microbiology specialist training at the Faculty of Medicine in Helsinki. They will review activities that could be counted in benefit of the Finnish specialist training scheme.	Completed

2) Outbreak Investigations:

Date:	Type of outbreak and your involvement:	Status:
28.45.5.09	General pandemic (H1N1) 2009 activities  Worked as a liaison between laboratory and epidemiologists at the Emergency Operations Centre	Completed
	Adviced epidemiologists and local health protection units on e.g. sampling, specimen materials, storage and transportation of specimens, timing of sampling, turnaround time, logistics, subtyping, antibody kinetics, and effect of previous immunity to the tests, testing of recovered cases	
	<ul> <li>Helped in composing information for the public concerning laboratory tests. Picked video footage filmed in the lab for national television channels.</li> </ul>	
	Adviced on laboratory safety issues and containment level.	
	<ul> <li>Adviced attending physicians of confirmed cases on required futher specimens</li> </ul>	
	Participated in writing Q&A for regional laboratories	
6.5.2009	Wrote an <b>overview of currently available Influenza A/H1N1 Virus Biosafety Guidelines for Laboratories</b> . This functioned as a background material for the discussions between the CfI and the Health and Safety Executive (HSE) on laboratory safety issues regarding H1N1.	Completed
7.5.2009	Wrote an <b>overview of currently available data on clinical manifestations and complications</b> associated with Influenza A/H1N1 virus.	Completed
May-July 2009	Pandemic (H1N1) 2009 Outbreak investigation in a school in London: observational descriptive study (with Laurence)  • Data collection	Completed Completed

	Data cleaning	Completed 12.5.2009
	Data analysis	Completed
	<ul> <li>Preliminary epidemiological report</li> </ul>	Completed
	Final report	Published 1/2010
	Journal article manuscript	
15.10.2009	Preparation of generic protocol for possible future H1N1 school outbreaks in the UK, including serosurveys.	Completed

3) Surveillance Activities:

3) Surveillance Activities:			
Date:	Type of surveillance and your involvement:	Status:	
1/2009- 5/2010	Creating a microbiological syndrome-based surveillance system for the <b>detection and investigation of undiagnosed serious infectious illnesses (USII)</b> • Major microbiological challenges identified  • Presented the first draft of the protocol to the working group on 2 April 2009 and further actions were decided.	Completed from my part (project ongoing)	
	<ul> <li>Checklist for firstline investigations created for all five syndromes.</li> </ul>		
1-8/2010	HAV seroepidemiology in Europe (ESEN2 project)		
	The epidemiology of Hepatitis A virus (HAV) is known to vary geographically. Only scattered data are available on HAV seroepidemiology in Europe, and uncertainties exist about the age-specific susceptibility and average age of infection. Aim: to identify susceptible age groups and level of endemicity to inform HAV vaccination policy in the participating countries: Belgium, Czech Republic, England, Finland, Germany, Italy, Lithuania, Malta, Romania, and Slovakia. Each country tested sera (n=1854–6748), collected in 1996–2004 as residual sera remaining from routine laboratory testing (7/10 countries), or by population-based random sampling (3/10), for total HAV antibodies. The local laboratory results were standardised to common units. Information on disease epidemiology and vaccine policy was collected.  • Data cleaning and analysis  • Manuscript and abstract  • Awaiting comments on the manuscript from country representatives (co-authors)	Completed 3/2010 Under preparation On-going	

#### 4) Research Activities:

	Activities:	Ctatura
Date:	Type of research and your involvement:	Status:
3/2009-10/2009	Investigation on the public health significance of newly identified picornaviruses in humans. Approaches: Conduct zoonotic and public health risk assessments of Saffold and Ljungan viruses; Develop and evaluated molecular and/or serological tools to investigate infection with these agents in human samples; Design study to assess prevalence of infections and any disease association.  • Major challenges are now gaining access to the virus strains used in the tests and the serum sample archives. Ljungan virus infectious clone has arrived to the lab, Ljungan virus culture supernatant will arrive within a week. Saffold: ? May take several months to gain access to the serum sample archives.  • Crude sample size calculations are being done  • Wrote COSHH risk assessment for handling these pathogens in laboratory  • The methodology has been developed with the help of related Mengovirus.	Project frozen
3.4.2009	Mumps seroprevalence and correlates of protection study, mumps outbreak Moldova, 2007- 2008.	Cancelled
15.1.2010	Reconstructing transmission trees from partially observed epidemic trees in a pandemic (H1N1) 2009 school outbreak. Data from the abovementioned H1N1 school outbreak are being used for modelling of transmission events in a school setting. This analysis allows e.g. estimation or reproductive numbers by time from onset of symptoms. My role with Laurence is to assist the modellers to understand and interpret our data. Analysis is finished and manuscript is under preparation.	Manuscript under preparation
8/2009- 5/2010	Public health significance of Hantaviruses in the UK. The hosts of hantaviruses Puumala (Myodes glareolus), Dobrava (Apodemus flavivollis) and Seoul (Rattus) are present in UK and these viruses, particularly Puumala virus, are widely found in their hosts in mainland Europe. In the UK, uncertainties exist about the presence of hantaviruses. Aim: to identify hantavirus infections in clinically suspected patients to contribute to assessing the public health significance of hantaviruses in the UK.  • Preparatory work  • sample shipment  • pre-planning the lab work in Helsinki  • Testing of specimens	Completed 3/2010 Completed 4/2010
	<ul> <li>Screening of convalescent sera for Avricolinae-borne hantavirus antibodies with Puumala IgG immunofluorescence assay (IFA), and for Murinae-borne hantavirus antibodies with Dobrava-Saaremaa IgG IFA.</li> <li>In case of (specific or unspecific) reactivity in IgG testing, the convalescent samples underwent Puumala IgM (bac-PUU-N) ELISA, and both samples Puumala and Dobrava-Saaremaa IgM IFA.</li> <li>Short report</li> <li>Abstract</li> </ul>	Completed 5/2010 Submitted

#### 5) Training activities:

<u>-                                    </u>	a firming accounts to		
Date:	Type of training followed:	Status:	
28.9 18.10.2008	EPIET introductory course, Menorca	Completed	

4.11.2008	Lecture: Pandemic Influenza Preparedness, CfI	Completed
11.11.2008	Journal Club, <b>CfI</b> (1h)	Completed
1921.11.2008	ESCAIDE conference, <b>Berlin</b>	Completed
15.12.2008	EPIET CTOI module, <b>Cyprus</b>	Completed
2728.11.2008	Pointers conference (on blood borne infections in	Completed
27. 20.11.2000	health care workers), <b>London</b>	Completed
17.12.2008	Rabies training, <b>CfI</b>	Completed
1316.1.2009	Train the trainer level course on Containment Level 3	Completed
1310.1.2009	Laboratory, Porton Down, <b>Salisbury</b>	Completed
16.3.2009	Wellcome Trust Advanced Course: Virus discovery in	Completed
10.3.2009	Clinical Setting, <b>Cambridge</b>	Completed
	Chilical Setting, Cambridge	
10.3.2009	Journal Club, <b>CfI</b> (1h)	Completed
24.3.2009	Video Training session on working in CL3 laboratory,	Completed
	CfI	
26.3.2009	Induction training session for Containment Level 3	Completed
	Laboratory, CfI	
2024.4.2009	EPIET Vaccinology module, <b>Helsinki</b>	Completed
1416.5.2009	ENIVD-CLRN annual meeting, <b>Prague</b>	Completed
14.6.2009	Basic Security in the Field, UN training and certificate	Completed
14.6.2009	Advanced Security in the Field, UN training and	Completed
	certificate	
2226.6.2009	EPIET Rapid Assesment module, <b>Bristol</b>	Completed
25.8.2009	Journal Club, <b>CfI</b> (1h)	Completed
31.84.9.2009	EUPHEM project review module, Rome	Completed
		'
1416.9.2009	Health Protection 2009 conference, University of	Completed
	Warwick, Coventry, UK	
69.10.2009	ECDC PRU Briefing, <b>Stockholm</b>	Completed
16.10.2009	HPA Encephalitis Study Grand Finale, BMA House,	Completed
	London	
2628.10.2009	ESCAIDE conference, <b>Stockholm</b>	Completed
25-26.2.2010	UK mini project review, CfI, London	Completed
9.3.2010	Journal Club, CfI (1h)	Completed
29.39.4.2010	Laboratory quality assurance and tools for survey and	Completed
	control of tropical diseases (module of Masters of	
	International Health 2009-2010 Erasmus Mundus:	
	tropical diseases), Bordeaux, France	
1012.6.2010	ENIVD-CLRN annual meeting, <b>Stockholm</b>	Completed
27.7.2010	European Workshop on Laboratory Diagnosis of	Completed
	Diphtheria (Lectures), CfI, London	
7-8/2010	A 5-week introduction round in the different	Completed
	units of the bacteriology department of the	
	HPA/Centre for Infections, including:	
	Antibiotic Resistance Monitoring & Reference	
	Laboratory	
	Department for Bioanalysis and Horizon	
	Technologies	
	Haemophilus reference unit	
	Streptococcus and Diphtheria Reference Unit	
	Laboratory of Health Care Associated Infection	
30.83.9.2010	EUPHEM-EPIET project review module, Rome	Upcoming
1415.9.2010	Health Protection 2010 conference, University of	Upcoming
	Warwick, Coventry, UK	
1113.11.2010	ESCAIDE conference, <b>Lisbon</b>	Upcoming

### 6) Teaching Activities:

7 : eu e :		
Date:	Type of teaching and your involvement:	Remarks:
2327.2.2009	Gave a lecture and facilitated in case study	Completed
	sessions in the "Laboratory Essentials for Field	-
	Epidemiologists" EPIET module, Bilthoven, Netherlands	

	Lecture: Virus diagnostic methods	
	Case study: Atypical pneumonia in a city in the Netherlands (Legionella)	
15.3.2010	<b>Group facilitation</b> , "Vaccinology", London School of Hygiene and Tropical Medicine	Completed
Preparation: 4-9/2010 Module: 810.9.2010	<ul> <li>UK Lab4epi module for local EPIET fellows and SpR:s. The aim is also to create a frame for future Lab4epi modules as to programme and training material. Organisation of the module together with Sabine Dittrich and Marie-Amelie Degail.</li> <li>Preparation of the module programme (with MAD and SD)</li> <li>Objectives</li> <li>Lecture topics</li> <li>Case study topic</li> <li>Order and timing of sessions</li> <li>Facilitators/lecturers</li> <li>Evaluation</li> <li>Modification of an existing case study and preparation of supporting material to fit the purpose of the module (with SD). Facilitation of the case study during the module.</li> <li>Lecture: Factors influencing a laboratory test result (by myself)</li> <li>Lecture: What is a public health laboratory? (with SD)</li> <li>Lecture: Using diagnostic tests for public health decision making (with SD)</li> <li>Interactive session to familiarise participants on commont lab terminology (with SD)</li> </ul>	Preparation ongoing

# 7) Communication:

Date:	Type of communication (including publications and presentations):	Remarks:
15.5.2009	Presentation: "EUPHEM training activities at HPA, London"	Presented
	ENIVD-CLRN annual meeting, Prague	
9.7.2009	Draft proposal on assessing the public health significance of arthropod-borne and rodent-borne viruses in the UK, including a risk assessment. To be presented for the Department of Health.	Presented
28.7.2009	Presentation:	Presented
	"Pandemic (H1N1) 2009 virus outbreak in a school in London, April-May 2009:observational study"	
	EPIET Seminar on H1N1 Investigations, ECDC, Stockholm	
15.9.2009	Conference abstract:	Presented (poster)
	L Calatayud, S Kurkela, P Neave, A Brock , S Perkins, M Zuckerman, M Catchpole, R Pebody, R Heathcock, H Maguire. New Influenza A(H1N1) Virus Outbreak in a School, South-East London, April-May 2009. <b>Health Protection 2009, Coventry, UK</b>	

27.10.2009	Conference abstract:	Presented (oral by LC)
	L Calatayud, S Kurkela, P Neave, A Brock, S Perkins, M Zuckerman, M Catchpole, R Pebody, R Heathcock, H Maguire. New Influenza A(H1N1) Virus Outbreak in a School, South-East London, April-May 2009. <b>ESCAIDE, Stockholm, Sweden</b>	
1.9.2009	Review article:	Published
	Kurkela S, Brown DWG. Molecular diagnostic techniques. <b>Medicine 2009;37:535-40.</b>	
7.10.2009	Presentation:	Presented
	"Pandemic (H1N1) 2009 virus outbreak in a school in London, April-May 2009". <b>ECDC PRU briefing week, ECDC, Stockholm</b>	
5.1.2010	Journal article:	Published
	Calatayud L, Kurkela S, Neave PE, Brock A, Perkins S, Zuckerman M, Sudhanva M, Bermingham A, Ellis J, Pebody R, Catchpole M, Heathcock R, Maguire H. Pandemic (H1N1) 2009 virus outbreak in a school in London: observational study. <b>Epidemiol Infect 2010;138:183-91.</b>	
25.3.2010	Presentation:	Presented
	"First experiences from the EUPHEM programme"	
	The 6 <sup>th</sup> National Focal Point Meeting, ECDC, Stockholm, Sweden	
7.5.2010	Factsheet:	Completed
	Preparation of <b>ECDC Factsheet on Sindbis virus infection</b> with ECDC PRU.	
13.5.2010	Presentation:	Presented
	Comparative Hepatitis A Seroepidemiology in 10 European Countries. <b>SpR Meeting, CfI.</b>	
26.5.2010	Book chapter:	Pre-final draft submitted
	Kurkela S, Brown DWG. Foot-and-mouth Disease, Vesicular Stomatitis, Newcastle Disease, and Swine Vesicular Disease. In: <b>Zoonoses - biology, clinical practice and public health control, 2nd Edition</b> , (SR Palmer, Lord Soulsby, David Brown, and Paul Torgerson, Editors). Oxford University Press. Oxford. U.K. Under preparation.	
11.6.2010	Presentation:	Presented
	EUPHEM training activities 2008-2010. <b>ENIVD-CLRN</b> annual meeting, <b>Stockholm</b>	
18.8.2010	Journal article manuscript:	Under preparation
	Kurkela S, Pebody R, Kafatos G, Nardone A, Andrews N, Pistol A, Davidkin I, Vranckx R, Nemecek V, Hesketh LM, Thierfelder W, Bruzzone B, Griskevicius A, Barbara C,	

	Sobotova Z, Miller E, Hatzakis A, Anastassopoulou CG. Comparative Hepatitis A Seroepidemiology in 10 European Countries.	
14.9.2010	Conference abstract/Presentation:  Comparative Hepatitis A Seroepidemiology in 10 European Countries. Health Protection 2010 conference, Coventry, UK	Upcoming; abstract accepted for oral presentation
Nov 2010	Conference abstract/Presentation:  Kurkela S, Pebody R, Kafatos G, Nardone A, Andrews N, Pistol A, Davidkin I, Vranckx R, Nemecek V, Hesketh LM, Thierfelder W, Bruzzone B, Griskevicius A, Barabara C, Sobotova Z, Miller E, Hatzakis A, Anastassopoulou CG. Comparative Hepatitis A Seroepidemiology in 10 European Countries.	Upcoming; abstract accepted for oral presentation
Nov 2010	Conference abstract:  Kurkela S, Brown D, Vapalahti O, Sivaprakasam V, Zochowski W, Smith R. No evidence of hantavirus infections in a series of 90 clinically suspected patients in the UK.	Upcoming; abstract accepted for poster presentation

# 8) Other:

Date:	Type of activity and your involvement:	Remarks:
12.11.2008	Wrote a report on the potential human pathogenicity of <b>Ljungan virus</b>	Completed
13.12.2008	Attended teleconferences regarding a fatal <b>anthrax</b> case in London.	Completed
28.2.2009	Wrote a <b>short introduction to EUPHEM</b> programme to EAN newsletter together with Sabine Dittrich	Completed
2.4.2009	Wrote a compulsory <b>COSHH risk assessment</b> for handling Saffold and Ljungan viruses in laboratory.	Completed
1.4.2009	Prepared a <b>presentation "Impact and effectiveness of Hib vaccine in the UK"</b> for the vaccinology module together with Jaran, Otilia and Laurence	Completed
4.11.2009	Identified and translated Finnish <b>guidelines on diagnosis and treatment of Lyme borreliosis</b> for a working group (lead by Dr Susan O'Connell at the Lyme Borreliosis Unit in Southampton). The working group is collecting a complete set of European guidelines.	Completed
2425.3.2010	Participated in the 6 <sup>th</sup> National Focal Point Meeting at ECDC  • Presentation (see above) and panel discussion (EUPHEM issues)  • Working group moderation (EUPHEM issues)  • Observation of the meeting (non-EUPHEM issues)	Completed